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Received April 3, 2013; accepted October 14, 2013AbstractBackground: Radical prostatectomy (RP) is one of the curative treatment options for patients with prostate cancer to achieve long-term survival,
but it is accompanied by potential complications. The Martin criteria used as a format for reporting complications has become standard in recent
years. However, it has not been applied in RP in Asian countries. In the present study, we investigated the early complications of RP developing
within 90 days in our institute according to the Martin criteria.
Methods: Between January 2003 and November 2011, patients with organ-confined adenocarcinoma of the prostate who received RP in our
institute were retrospectively reviewed. The operation was done as open RP, or minimally invasive RP, including laparoscopic RP and robot-
assisted laparoscopic RP (RaLP). The preoperative, operative, postoperative, and pathological parameters were recorded for analysis. Defini-
tions of complications were adopted from previous reports. Surgical and medical complications developed within 90 days postoperatively were
identified respectively; severity of each complication was classified according to ClavieneDindo classification. ClavieneDindo classification
grade III or higher complications were viewed as major complications.
Results: A total of 359 patients were included; 280 (78%) underwent open RP, 45 (12.5%) received laparoscopic RP, and 34 (9.5%) had RaLP.
The overall complication rate was 40.1%, and the major complication rate was 13.1%. There was no surgical mortality. Diarrhea requiring
conservative treatment (13.6%), minor urine leakage (9.5%), and gout attack (4.2%) were the leading complications. Minimally invasive RP had
higher rates of lymph leakage (p ¼ 0.015) and upper-extremity neuropathy (p ¼ 0.048). Body mass index >25 kg/m2 and use of neoadjuvant
hormone therapy were predictors for overall and major complications, whereas diabetes mellitus also predicted the development of major
complications. Besides lower case volume and learning curve for RaLP, patients’ higher age at surgery and higher risk for disease progression
compared to the Western series may be responsible for the higher complication rates.
Conclusion: The early complication rates of RP in our patients were slightly high compared to the Western series. By standardized report, being
overweight, diabetes mellitus, and use of neoadjuvant hormone therapy were identified as predictors of early complications in our series.
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Prostate cancer is one of the leading malignant neoplasms
among male Taiwanese. Treatment should be tailored indi-
vidually based on the risk of disease progression, life expec-
tancy at diagnosis, and possible complications of each
treatment modality, as well as the patient’s preference and
expected compliance. As the screening test with serumociation. All rights reserved.
Table 1
Definitions of complications of radical prostatectomy.
System Complications Severitya Definitions/management
Wound Prolonged wound pain I Intravenous opioid analgesics needed for
7 d or more postoperatively
Wound dehiscence IIIa Wound debridement under local
anesthesia in operation room
Wound infection I Wet dressing as wound care
Abscess formation IIIa Proved by sonography and treated
with aspiration
Prolonged lymph secretion I Drainage needed for >14 d, without
evidence of anastomosis leakage
Suture of drainage catheter IIIb Clinically evident, and explorative
laparotomy for removal
Urology Urinary leakage I Proved by cystography, and Foley catheter
retention for >14 d
IIIa Same as above, and change of Foley
catheter with cystoscopy
IIIb Same as above, and repair under general anesthesia
Significant hematuria I More severe than usual condition
II Resulting in acute urinary retention; Toomey
irrigation and blood transfusion needed
UTI/epididymitis II Clinically evident with positive urine culture,
treated with intravenous antibiotics
Acute urinary retention I Not due to hematuria; estimated residual urine
>150 mL or manual reinsertion of Foley catheter
Meatal stenosis IIIa Treated with urethral sounding under local anesthesia
Anastomotic stenosis II Proved by cystoscopy, and urethral sounding
under local anesthesia
IIIa Proved by cystoscopy, and transurethral incision
under spinal anesthesia/general anesthesia
Hydronephrosis IIIa Proved by sonography, and percutaneous nephrostomy
or double-J stenting needed
Distal ureteral injury IIIb Intraoperative repair
Dislodgment of Foley catheter IIIa Cystoscopy for reinsertion
Spontaneous clip voiding I Reported by the patient
Stitches in the urinary bladder IIIa Removed by cystoscopy
Hematology Postoperative blood transfusion II Postoperative hemoglobin <9e10 g/dL, or decreased
by >3 g/dL, and blood transfusion was done
Postoperative bleeding IIIb Reoperation because of postoperative bleeding
DIC II Clinically evident and proved by laboratory examinations
Neuromuscular disease Delirium II Clinically evident, treated with haloperidol
Gout attack II Clinically evident, treated with colchicine
Upper-extremity neuropathy I Observation and rehabilitation
Lower-extremity neuropathy I Observation and rehabilitation
Obturator nerve injury IIIb Intraoperative nerve repair
Rhabdomyolysis II Elevation of serum creatinine and myoglobin, treated
with hydration and alkalization of urine
Pressure sore I Grade I pressure sore, under observation and changing position
IIIa Pressure sores of grade II or more, and dressing needed
Compartment syndrome IIIb Emergent fasciotomy needed
Nephrology Hyponatremia I Treated with electrolytes supplement
Acute renal insufficiency I Postoperative serum creatinine >1.5 mg/dL in patients
with preoperative normal serum creatinine level
Gastroenterology Injury to rectal serosa I Intraoperative superficial injury without repair
Bowel injury IIIb Intraoperative bowel injury with repair
Ileus II Prolonged nil by mouth postoperatively and
gastrointestinal decompression needed
Stress ulcer II Clinically suspected, treated with proton pump inhibitor
Gastrointestinal bleeding II Positive occult blood reaction in stool or gastric juice,
treated with proton pump inhibitor
IIIa Upper GI endoscopy needed for hemostasis
Diarrhea I Observation without medical treatment
II Treated with antidiarrheal medication
Elevated liver function tests I Observation without medical treatment
Acute cholecystitis IIIa Clinically evident, treated with percutaneous drainage
(continued on next page)
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Table 1 (continued )
System Complications Severitya Definitions/management
Cardiology Tachyarrhythmia I Clinically evident, treated with electrolytes supplement
II Clinically evident, treated with antiarrhythmics
Acute coronary syndrome II Clinically evident, treated with antiangina agent
Postoperative hypertension II Clinically evident, treated with antihypertensive
medication
Intraoperative hypotension II Clinically evident, treated with inotropic agents
Dermatology Allergic exanthema II Clinically evident, treated with topical agent
Herpes zoster II Clinically evident, treated with topical agent
DIC ¼ disseminated intravascular coagulopathy; UTI ¼ urinary tract infection.
a Severity grade based on ClavieneDindo classification.
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has become widespread, more patients with prostate cancer
could be diagnosed at organ-confined status, making possible
more curative treatment, such as radical prostatectomy (RP),1
can be performed via open, laparoscopic, or robot-assisted
laparoscopic methods.2 These three approaches have compli-
cations in common, and each is also prone to additional spe-
cific complications. Development of complications not only
results in prolonged hospitalization and excessive costs, but
also endangers patients. Thus, studies focused on post-
operative complications are crucial. However, different defi-
nitions of complications as well as different categorization of
severity in different surgical series make comparisons difficult.
In 2002, Martin3 proposed the “Martin criteria” to evaluate the
quality of operative complication reports, and the criteria have
become the standard format in many surgical fields, including
urology. To our knowledge, there are no such standardized
complication reports concerning RP in Asian people. In the
present study, we retrospectively reviewed complications
developing within 90 days after RP in our institute and re-
ported them using the Martin criteria.
2. Methods
The preoperative, operative, and postoperative parameters
of patients with organ-confined adenocarcinoma of the pros-
tate receiving RP by any of 10 attending urologists in our
institute between January 1, 2003 and November 30, 2011
were retrospectively reviewed. The pathological details were
also recorded. The low, intermediate, or high risk for disease
progression was defined according to the National Compre-
hensive Cancer Network Guideline in Prostate Cancer Version
3 2010.4 The operation could be open RP (ORP) or minimally
invasive RP (MIRP), including laparoscopic RP (LRP) and
robot-assisted laparoscopic RP (RaLP, which was launched in
our institute in December 2009). Standards from the Martin
criteria modified by Donat et al5 for urological oncologic
surgery were used in this study. Surgical and medical com-
plications developing within 90 days postoperatively were
included as early complications. They were divided into eight
fields: including wound, urology, hematology, neuromuscular
disorder, nephrology, gastroenterology, cardiology, and
dermatology. Definitions of complications were adapted from
other RP complication reports,6e9 and graded according to theClavieneDindo classification.10 The definitions of complica-
tions are shown in Table 1. ClavieneDindo classification
grade III or higher was viewed as a major complication. Two-
sample t test and Fisher exact test were used for continuous
variables; Pearson c2 test and ManneWhitney U test were
used for categorical variables. A p value <0.05 was considered
significant.
3. Results
During the study period, a total of 363 consecutive patients
underwent RP in our institute. Four patients were excluded
because of rare histology (3 sarcoma and 1 basal cell carci-
noma). Median age at surgery was 67 years; median preop-
erative PSA was 9.37 ng/mL; 280 patients (78%) received
ORP, and 45 patients (12.5%) underwent LRP; RaLP was done
in 34 patients (9.5%). Because of similar physiological change
during operation and similar stage with regard to the learning
curve, we combined LRP and RaLP as MIRP for further
analysis. Other demographic data are shown in Table 2.
Patients receiving MIRP were older (p < 0.001), and,
although operation time was longer in the MIRP group
(p < 0.001), the amount of intraoperative blood loss
(p < 0.001) and intraoperative blood transfusion rate
(p < 0.001) were significantly lower than those in the ORP
group. However, more lymph nodes could be obtained during
ORP (p < 0.001), and there was a lower positive surgical
margin rate (p < 0.001). Duration for the postoperative
urethral catheterization was longer in the ORP group
(p < 0.001), but duration for the retention of drainage catheter
was shorter (p < 0.009). Postoperative follow-up was also
shorter in the MIRP group (p < 0.001). There was no statis-
tical difference between the two groups concerning other pa-
tient characteristics.
The detailed complications of RP are listed in Table 3. The
overall early complication rate was 40.1%, whereas the major
complication rate was 13.1% [including major surgical com-
plications (12%) and major medical complications (1.1%)].
There was no surgical mortality in our series. Diarrhea under
conservative treatment was the most common complication
(13.6%), followed by minor anastomotic leakage (9.5%) and
gout attack (4.2%). Compared to ORP, the MIRP group had
higher rates of lymph leakage (6.3%, p ¼ 0.015) and upper-
extremity neuropathy (2.5%, p ¼ 0.048).
Table 2
Demographic data of patients who underwent radical prostatectomy.
All ORP MIRP p
Patient numbers 359 (100.0) 280 (78.0) 79 (22.0)
Age, y 66.2  7.7 65.4  7.7 69.1  6.8 <0.001*
BMI, kg/m2 24.7  2.8 24.6  2.7 25.0  3.2 0.259
Preoperative PSA, ng/dL 14.46  19.44 15.07  20.03 12.17  16.96 0.252
Clinical stage T1 130 (36.2) 97 (34.6) 33 (41.8) 0.431
T2 186 (51.8) 146 (52.1) 40 (50.6)
T3 41 (11.4) 35 (12.5) 6 (7.6)
T4 2 (0.6) 2 (0.7) 0 (0)
TRUS Gleason score 6 198 (55.2) 162 (57.9) 36 (45.6) 0.147
7 106 (29.5) 75 (26.8) 31 (39.2)
8 53 (14.8) 41 (14.6) 12 (15.2)
Neoadjuvant hormone therapy 53 (14.8) 42 (15.0) 11 (13.9) 1
Prior abdominal operation 43 (12.0) 36 (12.9) 7 (8.9) 0.85
Charlson Comorbidity Index score 0 196 (54.6) 159 (56.8) 37 (46.8) 0.291
1 93 (25.9) 66 (23.6) 27 (34.2)
2 44 (12.3) 35 (12.5) 9 (11.4)
3 15 (4.2) 10 (3.6) 5 (6.3)
4 9 (2.5) 8 (2.9) 1 (1.3)
5 2 (0.6) 2 (0.7) 0 (0)
Operative ASA score 1 20 (6.1) 18 (7.1) 2 (2.7) 0.345
2 237 (72.3) 184 (72.2) 53 (72.6)
3 71 (21.6) 53 (20.8) 18 (24.7)
Operation time, min 378.8  135.9 337.1  102.7 520.9  130.1 <0.001*
EBL, mL 1495.7  1130.5 1763.9  1075.0 536.5  740.7 <0.001*
Intraoperative BT 243 (68.2) 236 (84.3) 9 (11.4) <0.001*
Prostate size, g 39.44  22.95 40.27  21.80 36.31  26.99 0.188
LN dissection numbers 7.3  5.2 8.1  5.3 4.6  3.3 <0.001*
Pathological stage 0 2 (0.6) 2 (0.7) 0 (0) 0.899
1 3 (0.8) 2 (0.7) 1 (1.3)
2 181 (50.4) 141 (50.4) 40 (50.6)
3 172 (47.9) 134 (47.9) 38 (48.1)
4 1 (0.3) 1 (0.4) 0 (0)
Operative Gleason score 6 98 (27.3) 80 (28.6) 18 (22.8) 0.243
7 215 (59.9) 166 (59.3) 49 (62.0)
8 46 (12.8) 34 (12.1) 12 (15.2)
Positive surgical margin 89 (24.8) 58 (20.7) 31 (39.2) 0.001*
SV invasion 50 (13.9) 43 (15.4) 7 (8.9) 0.197
Postoperative
Hospitalization, d 9.3  4.8 9.3  5.0 9.3  3.8 0.887
Foley catheterization, d 14.7  11.9 16.4  12.7 8.4  4.2 <0.001*
Drain retention, d 6.4  3.7 6.1  3.7 7.2  3.3 0.009*
Adjuvant hormone therapy 112 (31.2) 93 (33.2) 19 (24.1) 0.711
Adjuvant radiotherapy 15 (4.2) 9 (3.2) 6 (7.6) 0.108
Follow-up, mo 38.2  26.0 41.6  26.5 26.2  20.5 <0.001*
Data are presented as n (%) or mean  SD.
*p < 0.05.
ASA ¼ American Society of Anesthesiology; BMI ¼ body mass index; BT ¼ blood transfusion; EBL ¼ estimated blood loss; LN ¼ lymph nodes;
MIRP ¼ minimally invasive radical prostatectomy; ORP ¼ open radical prostatectomy; PSA ¼ prostate specific antigen; SV ¼ seminal vesicle;
TRUS ¼ transrectal ultrasound.
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operation time (p ¼ 0.008), estimated blood loss (p ¼ 0.023),
duration of urethral catheterization (p < 0.001) and drainage
catheter retention (p < 0.001), hospital stay (p < 0.001), use
of neoadjuvant hormone therapy (p ¼ 0.019), and adjuvant
hormone therapy (p ¼ 0.035) were associated with the
development of complications. BMI > 25 kg/m2 [odds ratio
(OR) 2.03, 95% confidence interval (CI) 1.31e3.15,
p ¼ 0.002] and neoadjuvant hormone therapy (OR 1.97, 95%
CI 1.07e3.62, p ¼ 0.029) were significant risk factors foroverall complications on multivariate analysis. As for major
complications, BMI (p ¼ 0.008), duration of urethral cathe-
terization (p < 0.001) and drainage catheter (p ¼ 0.007),
hospital stay (p < 0.001), presence of comorbidities of type 2
diabetes (p ¼ 0.037) and severe renal disease (p ¼ 0.032),
and use of adjuvant hormone therapy (p ¼ 0.013) were pre-
dictive in univariate analysis, but only BMI > 25 kg/m2 (OR
2.48, 95% CI 1.28e4.81, p ¼ 0.007) and type 2 diabetes (OR
2.54, 95% CI 1.16e5.55, p ¼ 0.019) reached statistical sig-
nificance in multivariate analysis (Table 4). As for minor
Table 3
Complications of radical prostatectomy within 90 days.
Severity
grade
All (%) ORP (%) MIRP (%) p
All complications 144 (40.1) 110 (39.3) 34 (43.0) 0.624
Major complications III þ IV 47 (13.1) 41 (14.6) 6 (7.6) 0.386
Surgical complications 108 (30.1) 84 (30.0) 24 (30.4) 0.234
Major III þ IV 43 (12.0) 37 (13.2) 6 (7.6) 0.536
Minor I þ II 65 (18.1) 47 (16.8) 18 (22.8) 0.504
Medical complications 55 (15.3) 41 (14.6) 14 (17.7) 0.314
Major III þ IV 4 (1.1) 4 (1.4) 0 (0) 0.580
Minor I þ II 51 (14.2) 37 (13.2) 14 (17.7) 0.069
Wound 31 (8.6) 20 (7.1) 11 (13.9) 0.070
Prolonged wound pain I 4 (1.1) 3 (1.1) 1 (1.3) 1.000
Wound dehiscence IIIa 8 (2.2) 8 (2.9) 0 (0) 0.208
Wound infection I 5 (1.4) 3 (1.1) 2 (2.5) 0.308
Abscess formation IIIa 4 (1.1) 2 (0.7) 2 (2.5) 0.215
Suture of drainage
catheter
IIIb 1 (0.3) 1 (0.4) 0 (0) 1.000
Prolonged lymph
secretion
I 8 (2.2) 3 (1.1) 5 (6.3) 0.015*
Urology 76 (21.2) 59 (21.1) 17 (21.5) 0.499
Urinary leakage I 34 (9.5) 26 (9.3) 8 (10.1) 0.829
IIIa 1 (0.3) 1 (0.4) 0 (0) 1.000
IIIb 1 (0.3) 1 (0.4) 0 (0) 1.000
Significant hematuria I 6 (1.7) 5 (1.8) 1 (1.3) 1.000
II 7 (1.9) 7 (2.5) 0 (0) 0.355
UTI/epididymitis II 6 (1.7) 4 (1.4) 2 (2.5) 0.617
Acute urinary retention I 8 (2.2) 5 (1.8) 3 (3.8) 0.381
Meatal stenosis IIIa 5 (1.4) 4 (1.4) 1 (1.3) 1.000
Anastomotic stenosis II 1 (0.3) 1 (0.4) 0 (0) 1.000
IIIa 13 (3.6) 11 (3.9) 2 (2.5) 0.741
Hydronephrosis IIIa 1 (0.3) 1 (0.4) 0 (0) 1.000
Distal ureteral injury IIIb 1 (0.3) 1 (0.4) 0 (0) 1.000
Dislodgement of Foley
catheter
IIIa 7 (1.9) 7 (2.5) 0 (0) 0.355
Spontaneous clip voiding I 1 (0.3) 1 (0.4) 0 (0) 1.000
Stitches in urinary
bladder
IIIa 1 (0.3) 1 (0.4) 0 (0) 1.000
Hematology 12 (3.3) 12 (4.3) 0 (0) 0.076
Postoperative blood
transfusion
II 10 (2.8) 10 (3.6) 0 (0) 0.126
Postoperative bleeding IIIb 1 (0.3) 1 (0.4) 0 (0) 1.000
DIC II 1 (0.3) 1 (0.4) 0 (0) 1.000
Neuromuscular disorder 13 (3.6) 8 (2.9) 5 (6.4) 0.104
Delirium II 1 (0.3) 0 (0) 1 (1.3) 0.220
Gout attack II 15 (4.2) 13 (4.6) 2 (2.5) 0.537
Upper-extremity
neuropathy
I 2 (0.6) 0 (0) 2 (2.5) 0.048*
Lower-extremity
neuropathy
I 4 (1.1) 3 (1.1) 1 (1.3) 1.000
Obturator nerve injury IIIb 1 (0.3) 1 (0.4) 0 (0) 1.000
Rhabdomyolysis II 1 (0.3) 1 (0.4) 0 (0) 1.000
Pressure sore I 2 (0.6) 1 (0.4) 1 (1.3) 0.392
IIIa 2 (0.6) 1 (0.4) 1 (1.3) 0.392
Compartment syndrome IIIb 2 (0.6) 1 (0.4) 1 (1.3) 0.392
Nephrology 5 (1.4) 3 (1.1) 2 (2.5) 0.304
Hyponatremia I 1 (0.3) 1 (0.4) 0 (0) 1.000
Acute renal insufficiency I 4 (1.1) 2 (0.7) 2 (2.5) 0.212
Gastroenterology 23 (6.4) 18 (6.4) 5 (6.4) 0.155
Injury to rectal serosa I 1 (0.3) 1 (0.4) 0 (0) 1.000
Bowel injury IIIB 2 (0.6) 2 (0.7) 0 (0) 1.000
Ileus II 11 (3.1) 7 (2.5) 4 (5.1) 0.268
Stress ulcer II 1 (0.3) 0 (0) 1 (1.3) 0.220
Gastrointestinal bleeding II 2 (0.6) 1 (0.4) 1 (1.3) 0.392
IIIa 2 (0.6) 2 (0.7) 0 (0) 1.000
Diarrhea I 38 (10.6) 31 (11.1) 7 (8.9) 0.682
Table 3 (continued )
Severity
grade
All (%) ORP (%) MIRP (%) p
II 11 (3.1) 9 (3.2) 2 (2.5) 1.000
Elevated liver function
tests
I 3 (0.8) 3 (1.1) 0 (0) 1.000
Acute cholecystitis IIIa 2 (0.6) 2 (0.7) 0 (0) 1.000
Cardiology 8 (2.2) 7 (2.5) 1 (1.3) 1.000
Tachyarrhythmia I 2 (0.6) 2 (0.7) 0 (0) 1.000
II 2 (0.6) 1 (0.4) 1 (1.3) 0.392
Acute coronary
syndrome
II 2 (0.6) 2 (0.7) 0 (0) 1.000
Postoperative
hypertension
II 1 (0.3) 1 (0.4) 0 (0) 1.000
Intraoperative
hypotension
II 1 (0.3) 1 (0.4) 0 (0) 1.000
Dermatology 9 (2.5) 7 (2.5) 2 (2.5) 1.000
Allergic exanthema II 8 (2.2) 6 (2.1) 2 (2.5) 0.690
Herpes zoster II 1 (0.3) 1 (0.4) 0 (0) 1.000
*p < 0.05.
DIC ¼ disseminated intravascular coagulopathy; MIRP ¼ minimally invasive
radical prostatectomy; ORP ¼ open radical prostatectomy; UTI ¼ urinary tract
infection.
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analysis in the present study.
We compare the complications of ORP and MIRP of our
series to those of other Western standardized reports in Table
59,11 and Table 6,6,7,9,11e13 respectively. Overall complication
rate of ORP (39.3%) was comparable to that in other series,
but there was a higher major complication rate in our study
(14.6%). By contrast, our MIRP series had higher overall
(43%) and major complication rates (7.6%) than did the pure
RaLP series, but were comparable to those of pure LRP
reports.
4. Discussion
Complications of surgery, which may vary in different
countries, are key information for patients in making
informed decisions. Well-documented complication reports
have been published in Western countries, but a comprehen-
sive report concerning RP is not yet available in Taiwan.
Patients with prostate cancer in Taiwan might not be able to
undergo RP by their own choice, which may potentially
damage the patientephysician relationship. Moreover,
communication and comparison among different complication
reports could improve the understanding of specific surgeries
and hence, prevent the development of complications. How-
ever, patient selection, tumor selection, and surgical experi-
ence, as well as assessment tools, definitions, and the time at
which the evaluation is performed, will influence the pre-
sentation of postoperative outcome. The Martin criteria pro-
vides a standardized system to ensure consistency and clarity
in reporting. A true comparison across different series or
surgical approaches may be possible in such situations,3 but it
may be expensive and time-consuming to analyze and present
the complications fulfilling the Martin criteria. Lack of
consensus on complication definitions is also an issue. This
Table 4
Univariate and multivariate analyses of risk factors for all and major complications of radical prostatectomy.
All complications Major complications
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
No Yes p No Yes p
Age, y 65.9  7.5 66.6  8.0 0.447 66.0  7.7 67.7  7.7 0.161
BMI >25 kg/m2 78 (37.3) 75 (54.0) 0.003 p ¼ 0.002
95% CI 1.305e3.148
125 (41.1) 28 (63.6) 0.005 p ¼ 0.007
95% CI 1.275e4.807
Preoperative PSA, ng/mL 14.3  20.9 14.7  17.1 0.829 14.2  19.9 16.0  15.9 0.555
TRUS Gleason score 6 122 (56.7) 76 (53.5) 0.1 172 (55.3) 26 (56.5) 0.093
7 68 (31.6) 38 (26.8) 97 (31.2) 9 (19.6)
8 25 (11.6) 28 (19.7) 42 (13.5) 11 (23.9)
cT cT1 75 (34.9) 55 (38.2) 0.573 114 (36.5) 16 (34.0) 0.44
cT2 117 (54.4) 69 (47.9) 162 (51.9) 24 (51.1)
cT3 22 (10.2) 19 (13.2) 35 (11.2) 6 (12.8)
cT4 1 (0.5) 1 (0.7) 1 (0.3) 1 (2.1)
Risk groups Low 55 (25.6) 43 (29.9) 0.255 87 (27.9) 11 (23.4) 0.802
Intermediate 136 (63.3) 79 (54.9) 185 (59.35) 30 (63.8)
High 24 (11.2) 22 (15.3) 40 (12.8) 6 (12.8)
ASA score 1 14 (7.2) 6 (4.5) 0.37 17 (6.0) 3 (7.0) 0.842
2 135 (69.6) 102 (76.1) 207 (72.6) 30 (69.8)
3 45 (23.2) 26 (19.4) 61 (21.4) 10 (23.3)
Charlson Comorbidity Index 0 117 (54.4) 79 (54.9) 0.823 174 (55.8) 22 (46.8) 0.512
1 54 (25.1) 39 (27.1) 79 (25.3) 14 (29.8)
2 44 (20.5) 26 (18.1) 59 (18.9) 11 (23.4)
Myocardial infarction 2 (0.9) 1 (0.7) 1 2 (0.6) 1 (2.1) 0.344
Heart failure 1 (0.5) 2 (1.4) 0.567 3 (1.0) 0 (0) 1
Coronary artery disease 24 (11.2) 17 (11.8) 0.851 35 (11.2) 6 (12.8) 0.756
Cerebrovascular accident 7 (3.3) 5 (3.5) 1 11 (3.5) 1 (2.1) 1
Peripheral arterial occlusion disease 5 (2.3) 2 (1.4) 0.707 5 (1.6) 2 (4.3) 0.23
Chronic obstructive pulmonary disease 6 (2.8) 4 (2.8) 1 8 (2.6) 2 (4.3) 0.626
Gastric ulcer 29 (13.5) 16 (11.1) 0.505 40 (12.8) 5 (10.6) 0.674
Autoimmune disease 5 (2.3) 0 (0) 0.086 5 (1.6) 0 (0) 1
Mild liver disease 13 (6.0) 7 (4.9) 0.631 18 (5.8) 2 (4.3) 1
Type 2 diabetes 26 (12.1) 23 (16) 0.294 38 (12.2) 11 (23.4) 0.037 p ¼ 0.019
95% CI 1.162e5.549
Lymphoma 1 (0.5) 1 (0.7) 1 1 (0.3) 1 (2.1) 0.245
Severe renal disease 2 (0.9) 4 (2.8) 0.224 3 (1.0) 3 (6.4) 0.032 p ¼ 0.085
95% CI 0.799e33.507
Solid tumor 17 (7.9) 12 (8.3) 0.884 25 (8.0) 4 (8.5) 0.781
Severe liver disease 1 (0.5) 0 (0) 1 1 (0.3) 0 (0) 1
Preoperative antiandrogen usage 24 (11.2) 29 (20.1) 0.023 p ¼ 0.029
95% CI 1.073e3.623
43 (13.8) 10 (21.3) 0.177
Preoperative TURP 16 (7.4) 12 (8.3) 0.758 25 (8.0) 3 (6.4) 1
Prior other abdominal surgery 29 (13.5) 18 (12.5) 0.786 39 (12.5) 8 (17.0) 0.392
Operation route ORP 170 (79.1) 110 (76.4) 0.604 239 (76.6) 41 (87.2) 0.101
MIRP 45 (20.9) 34 (23.6) 73 (23.4) 6 (12.8)
Lymph node dissection numbers 7.6  2.8 6.9  5.0 0.717 7.4  5.2 7.0  5.2 0.616
Intraoperative blood transfusion 145 (67.4) 100 (69.4) 0.69 212 (67.9) 33 (70.2) 0.765
Pathological stage 3 106 (49.3) 67 (46.5) 0.606 152 (48.7) 21 (44.7) 0.606
Pathological nodal status N0 209 (97.2) 136 (94.4) 0.149 300 (96.2) 45 (95.7) 0.724
N1 5 (2.3) 8 (5.6) 11 (3.5) 2 (4,3)
N2 1 (0.5) 0 (0) 1 (0.3) 0 (0)
Positive surgical margin 52 (24.2) 37 (25.7) 0.746 78 (25.0) 11 (23.4) 0.813
Seminal vesicle invasion 26 (12.1) 24 (16.7) 0.22 42 (13.5) 8 (17.0) 0.511
Data are presented as n (%) or mean  SD.
ASA ¼ American Society of Anesthesiology; BMI ¼ body mass index; CI ¼ confidence interval; MIRP ¼ minimally-invasive radical prostatectomy; ORP ¼ open
radical prostatectomy; PSA ¼ prostate specific antigen; TRUS ¼ transrectal ultrasound; TURP ¼ transurethral resection of the prostate.
239W.-M. Cheng et al. / Journal of the Chinese Medical Association 77 (2014) 234e241awaits development by professional societies focused on
particular diseases and surgical approaches. As the severity
grading system depends on the intervention to manage a
complication, clinically significant functional complications
may be missed. Moreover, interobserver variability due to thesubjective nature of the grading system may exist.14 The
Martin criteria has become the mainstay in Europe and in the
USA, but to our knowledge, the present study is the first
standardized report of complications of RP in an Asian
country.
Table 5
Comparison of complications of open radical prostatectomy with other pub-
lished series.
Rabbani9 Charlsson11 VGH-TPE
Patient numbers 3458 485 280
Age, y 59.4 63 66
BMI, kg/m2 27.7 24.5
PSA 5.6 7.4 9.32
Clinical stage T1 59.5 51.8 34.6
T2 36.9 37.8 52.1
T3 3.5 10.4 12.5
TRUS Gleason score 6 58.7 57.9
7 32.6 26.8
8 8.8 14.6
Overall complications 39.6 38.5 39.3
All major complications 16.3 6.8 14.6
Surgical complications 28 36.3 30
Major surgical complications 14.7 5.4 13.2
Medical complications 11.6 2.2 14.6
Major medical complications 1.6 1.4 1.4
Data are presented as %, unless otherwise indicated.
BMI ¼ body mass index; PSA ¼ prostate specific antigen; TRUS ¼ transrectal
ultrasound; VGH-TPE ¼ Veterans General Hospital, Taipei.
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surgical treatment approaches in our institute were higher,
especially that for MIRP. A smaller case number and learning
curve may influence the development of complications.15,16 A
higher risk for disease progression, presenting as higher serum
PSA, higher clinical stage, and higher biopsy Gleason score,
as well as older age in our patient group compared to other
series, may also help explain the higher complication rates.
Being overweight (BMI > 25 kg/m2), the presence of co-
morbidity of diabetes mellitus, and use of neoadjuvant hor-
mone therapy were predictors of overall and major
complications in our patients. This finding is similar to the
findings from the Memorial Sloan Kettering Cancer Center;
Rabbani et al9 suggested that greater BMI, CharlsonTable 6
Comparison of complications of minimally invasive radical prostatectomy with ot
Author Rabbani et al9 Hruza et al7 Carlsson
Route LRP LRP RALP
Patient numbers 1134 2200 1253
Age, y 59.7 63.8 62
BMI, kg/m2 27.6 26.8
PSA, ng/mL 5.3 7.6 6.3
Clinical stage T1 71.3 61.5
T2 26.1 34.7
T3 2.6 3.8
TRUS Gleason score 6 57.3 42.6
7 36.9 48.1
8 5.8 9.3
Overall complications 57.1 28.5 8.8
All major complications 13 6.8 3.5
Surgical complications 38.5 24.3 8.6
Major surgical complications 10.7 6 3.3
Medical complications 18.6 4.3 0.2
Major medical complications 2.3 0.8 0.2
Data are presented as %, unless otherwise indicated.
BMI ¼ body mass index; LRP ¼ laparoscopic radical prostatectomy; MIRP ¼
RaLP ¼ robot-assisted laparoscopic radical prostatectomy; TRUS ¼ transrectal ulcomorbidities score (especially diabetes mellitus), neo-
adjuvant hormone therapy, ethnicity, larger prostate size,
higher biopsy Gleason score, ORP, and greater estimated
blood loss, are predictors for the development of complica-
tions. Patients with diabetes mellitus are more at risk of poor
wound healing, respiratory infection, myocardial infarction,
and increased length of hospital stay when undergoing cardiac
and noncardiac surgeries.17 However, in other series, obese
patients had prolonged operation time and increased estimated
blood loss, especially during the learning curve, but failed to
show association with higher complication rates.18e21 Simi-
larly, because of increased surgical difficulty, prolonged
operation time and increased estimated blood loss were also
observed in patients who received neoadjuvant hormone
therapy, but there was no significant difference when it came
to complication rates.22 The current consensus is that no
neoadjuvant hormonal therapy should be given because it has
no obvious benefit in disease control whereas it may adversely
affect surgical outcome;23,24 furthermore, in our experience, it
may confer a higher surgical complication rate of RP.
There were several limitations of the present study. First,
this was a retrospective analysis, and hence minor complica-
tions might not be described as precisely as in prospective
studies. Second, the study was based on a single center, which
may not be representative of the whole nation’s experience.
Third, all the surgeries were not done by a single urologist,
and differences in surgical skill and experience may also have
confounded the analysis of complications.
In conclusion, by standardized report, the early complica-
tion rates of RP in our patients were slightly higher compared
to Western series. Higher patient age and higher risk for dis-
ease progression may be important to this difference.
BMI > 25 kg/m2, diabetes mellitus, and use of neoadjuvant
hormone therapy were predictors of development of early
complications in our series.her published series.
et al11 Novara et al12 Coelho et al13 Agarwal et al6 VGH-TPE
RALP RALP RALP MIRP
415 2500 3317 79
62.3 61 60 70
26.6 28 27 25.1
6.4 4.9 5 9.42
74 41.8
24 50.6
2 8
74 64 50 45.6
17.3 28.5 39.5 39.2
4.5 7.5 10.1 15.2
21.6 5.6 9.5 43
3.2 1.1 2.5 7.6
4.1 7.3 30.4
0.6 2.4 7.6
1.5 2.3 17.8
0.4 0.2 0
minimally invasive radical prostatectomy; PSA ¼ prostate specific antigen;
trasound; VGH-TPE ¼ Veterans General Hospital, Taipei.
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